These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18272670)

  • 1. Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis.
    Balada E; Simeón-Aznar CP; Ordi-Ros J; Rosa-Leyva M; Selva-O'Callaghan A; Pardos-Gea J; Fonollosa-Pla V; Vilardell-Tarrés M
    Ann Rheum Dis; 2008 Jul; 67(7):1027-9. PubMed ID: 18272670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.
    Loizos N; Lariccia L; Weiner J; Griffith H; Boin F; Hummers L; Wigley F; Kussie P
    Arthritis Rheum; 2009 Apr; 60(4):1145-51. PubMed ID: 19333919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.
    Baroni SS; Santillo M; Bevilacqua F; Luchetti M; Spadoni T; Mancini M; Fraticelli P; Sambo P; Funaro A; Kazlauskas A; Avvedimento EV; Gabrielli A
    N Engl J Med; 2006 Jun; 354(25):2667-76. PubMed ID: 16790699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
    Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
    Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis.
    Hasegawa M; Sato S; Yanaba K; Komura K; Yamazaki M; Takehara K
    Ann Rheum Dis; 2004 Nov; 63(11):1514-7. PubMed ID: 15479907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis.
    Costa S; Mondini M; Caneparo V; Afeltra A; Airò P; Bellisai F; Faggioli P; Gerli R; Lotzniker M; Meroni PL; Morozzi G; Radice A; Riccieri V; Scarsi M; Sebastiani GD; Sinico RA; Tincani A; Gariglio M; Landolfo S
    Rheumatology (Oxford); 2011 Apr; 50(4):674-81. PubMed ID: 21134960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis.
    Moroncini G; Grieco A; Nacci G; Paolini C; Tonnini C; Pozniak KN; Cuccioloni M; Mozzicafreddo M; Svegliati S; Angeletti M; Kazlauskas A; Avvedimento EV; Funaro A; Gabrielli A
    Arthritis Rheumatol; 2015 Jul; 67(7):1891-903. PubMed ID: 25808833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
    Kuwatsuka Y; Ogawa F; Iwata Y; Komura K; Muroi E; Hara T; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies specific for alpha-enolase in systemic autoimmune disorders.
    Pratesi F; Moscato S; Sabbatini A; Chimenti D; Bombardieri S; Migliorini P
    J Rheumatol; 2000 Jan; 27(1):109-15. PubMed ID: 10648026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
    Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered diurnal rhythm of prolactin in systemic sclerosis.
    Hilty C; Brühlmann P; Sprott H; Gay RE; Michel BA; Gay S; Neidhart M
    J Rheumatol; 2000 Sep; 27(9):2160-5. PubMed ID: 10990228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis.
    Classen JF; Henrohn D; Rorsman F; Lennartsson J; Lauwerys BR; Wikström G; Rorsman C; Lenglez S; Franck-Larsson K; Tomasi JP; Kämpe O; Vanthuyne M; Houssiau FA; Demoulin JB
    Arthritis Rheum; 2009 Apr; 60(4):1137-44. PubMed ID: 19333949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
    Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
    Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis--preliminary report.
    Sulik A; Kowal-Bielecka O; Domysławska I; Chwiećko J; Sierakowski S
    Rocz Akad Med Bialymst; 2005; 50 Suppl 1():228-31. PubMed ID: 16119673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
    Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
    Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis.
    Liakouli V; Manetti M; Pacini A; Tolusso B; Fatini C; Toscano A; Cipriani P; Guiducci S; Bazzichi L; Codullo V; Ruocco L; Dell'orso L; Carubbi F; Marrelli A; Abbate R; Bombardieri S; Ferraccioli G; Montecucco C; Valentini G; Matucci-Cerinic M; Ibba-Manneschi L; Giacomelli R
    Ann Rheum Dis; 2009 Apr; 68(4):584-90. PubMed ID: 18445624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.